“Such wearable sweat sensors have the potential to rapidly, continuously, and noninvasively capture changes in health at molecular levels,” Gao says. “They could enable personalized monitoring, early diagnosis, and timely intervention.”
The development of such sensors would allow doctors to continuously monitor the condition of patients with illnesses like cardiovascular disease, diabetes, or kidney disease, all of which result in abnormal levels of nutrients or metabolites in the bloodstream. Patients would benefit from having their physician better informed of their condition, while also avoiding invasive and painful encounters with hypodermic needles.
Gao’s work is focused on developing devices based on microfluidics, a name for technologies that manipulate tiny amounts of liquids, usually through channels less than a quarter of a millimeter in width. Microfluidics are ideal for an application of this sort because they minimize the influence of sweat evaporation and skin contamination on the sensing accuracy. As freshly supplied sweat flows through the microchannels, the device can make more accurate measurements of sweat and can capture temporal changes in concentrations.
From a Radiological Society of North America release:
The TACT Pivotal study of MRI-guided TULSA for whole-gland ablation in men with localized prostate cancer met its primary PSA endpoint in 96% of patients, with low rates of severe toxicity and residual GG2 disease. MRI at 12mo detected residual disease with NPV of 93%.
The new technique is called MRI-guided transurethral ultrasound ablation (TULSA) and has been under development for a number of years. The minimally invasive technology involves a rod that enters the prostate gland via the urethra and emits highly controlled sound waves in order to heat and destroy diseased tissue, while leaving healthy tissue unharmed.
It was all horribly familiar — a rerun of an episode 15 months earlier, when she was with her family in River Vale, N.J. Back then, the burning pressure sent her to the emergency department, and she was told the same thing: She was having a heart attack. Immediately the cardiologist looked for blockages in the coronary arteries, which feed blood and oxygen to the hardworking muscles of her heart. That was the cause of most heart attacks. But they found no blockage.
Since childhood, she had frequent terrible canker sores that lasted for weeks. Sometimes it was hard to eat or even talk. Her mother, a nurse, told her everybody got them and thought she was being dramatic when she complained. So she had never brought them up with her doctors. Now the woman saw that her answer somehow made sense to the rheumatologist.
Indeed, that was the clue that led the rheumatologist to a likely diagnosis: Behcet’s disease. It’s an unusual inflammatory disorder characterized by joint pains, muscle pains and recurrent ulcers in mucus membranes throughout the body. Almost any part of the body can be involved — the eyes, the nose and lungs, the brain, the blood vessels, even the heart. Behcet’s was named after a Turkish dermatologist who in 1937 described a triad of clinical findings including canker sores (medically known as aphthous ulcers), genital ulcers and an inflammatory condition of the eye.
Philips Lumify ultrasound technology is an important component of the mobile ECMO unit. Members of the ECMO team use Lumify for real-time visual guidance when inserting tubes in veins and arteries in a process called ECMO cannulation.
“Lumify has excellent image quality and is easy to use – it was instrumental in our first pre-hospital ECMO cannulation,” said Dr. Darren Braude.
Physicians from the University of New Mexico (UNM) and local emergency responders recently treated a cardiac arrest patient with the first ever out-of-hospital portable life-support system available in the United States.
The machine performs a function called extracorporeal membrane oxygenation, or ECMO. ECMO machines mimic a functioning heart and lungs, circulating oxygenated blood for patients who have suffered a cardiac arrest.